Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases

Annals of Surgical Oncology

Volumn 19, Issue 9, 2012, Pages 2937-2945

  Inoue, Tatsushi ^a   Yachida, Shinichi ^a   Usuki, Hisashi ^a   Kimura, Tomoki ^a   Hagiike, Masanobu ^a   Okano, Keiichi ^a   Suzuki, Yasuyuki ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MALE; MORBIDITY; PILOT STUDY; PROSPECTIVE STUDY; RADIATION DOSE; SEPSIS; STOMACH CANCER; STOMACH SURGERY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANOREXIA; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMORADIOTHERAPY, ADJUVANT; DOSE FRACTIONATION; DRUG COMBINATIONS; FEMALE; GASTRECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NAUSEA; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; OXONIC ACID; PILOT PROJECTS; STOMACH NEOPLASMS; TEGAFUR;

EID: 84867405508     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2332-4     Document Type: Article

References (41)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Maruyama K, Kaminishi M, Hayashi K, et al. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer. 2006;9:51-66.
3. Cheng CT, Tsai CY, Hsu JT, et al. Aggressive surgical approach for patients with T4 gastric carcinoma: promise or myth? Ann Surg Oncol. 2011;18:1606-14.
4. Yoshikawa T, Sasako M, Yamamoto S, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015-22.
5. Kinoshita T, Sasako M, Sano T, et al. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer. 2009;12:37-42.
6. American Society of Clinical Oncology. A phase II study of preoperative chemotherapy (CX) with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancer: JCOG 0210.. 2007. http://meeting.ascopubs.org/cgi/content/abstract/25/18-suppl/4609.
7. American Society of Clinical Oncology. A phase II study of preoperative chemotherapy with S-1 (S) and cisplatin (P) followed by D3 gastrectomy for gastric cancer (GC) with extensive lymph node metastasis (ELM): survival results of JCOG0405.. 2011. http://meeting.ascopubs.org/cgi/content/abstract/29/4- suppl/70?sid=e4089844-199e-4af0-9346-5e0903d6eff7.
8. Yoshikawa T, Omura K, Kobayashi O, et al. A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). Eur J Surg Oncol. 2010;36:546-51.
9. American Society of Clinical Oncology. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced gastric cancer.. 2011. http://meeting.ascopubs.org/cgi/content/abstract/29/15- suppl/4057?sid=10b08cb7-9ebf-4699-b2a9-478646f2074a.
10. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 2nd English ed. Gastric Cancer. 1998;1:10-24.
11. Japanese classification of gastric carcinoma-2nd English edition-response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer. 2001;4:1-8.
12. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953-8.
13. Fujitani K, Ajani JA, Crane CH, et al. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007;14:2010-7.
14. Saikawa Y, Kubota T, Takahashi T, et al. Is chemoradiation effective or harmful for stage VI gastric cancer patients? Oncol Rep. 2005;13:865-70.
15. Shirasaka T, Nakano K, Takechi T, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res. 1996;56:2602-6.
16. Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548-57.
17. Sugimachi K, Maehara Y, Horikoshi N, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group. Oncology. 1999;57:202-10.
18. Koizumi W, Kurihara M, Nakano S, et al. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191-7.
19. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-20.
20. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnairebased study. Lancet Oncol. 2006;7:903-9.
21. Kim YH, Lee KH, Park SH, et al. Staging of T3 and T4 gastric carcinoma with multidetector CT: added value of multiplanar reformations for prediction of adjacent organ invasion. Radiology. 2009;250:767-75.
22. Ikeguchi M, Katano K, Saitou H, et al. Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma. Hepatogastroenterology. 1997;44:866-71.
23. Hwang GI, Yoo CH, Sohn BH, et al. Predictive value of preoperative serum CEA, CA19-9 and CA125 levels for peritoneal metastasis in patients with gastric carcinoma. Cancer Res Treat. 2004;36:178-81.
24. Harada K, Kawaguchi S, Supriatno, et al. Enhancement of apoptosis in salivary gland cancer cells by the combination of oral fluoropyrimidine anticancer agent (S-1) and radiation. Int J Oncol. 2004;25:905-11.
25. Harada K, Kawaguchi S, Supriatno, et al. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol. 2004;40:713-9.
26. Harada H, Omura K. Preoperative concurrent chemotherapy with S-1 and radiotherapy for locally advanced squamous cell carcinoma of the oral cavity: phase I trial. J Exp Clin Cancer Res. 2010;29:33.
27. Roth AD, Allal AS, Brundler MA, et al. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: a phase I-II study. Ann Oncol. 2003;14:110-5.
28. Lowy AM, Feig BW, Janjan N, et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol. 2001;8:519-24.
29. Balandraud P, Moutardier V, Giovannini M, et al. Locally advanced adenocarcinomas of the gastric cardia: results of preoperative chemoradiotherapy. Gastroenterol Clin Biol. 2004;28:651-7.
30. Klautke G, Foitzik T, Ludwig K, et al. Neoadjuvant radiochemotherapy in locally advanced gastric carcinoma. Strahlenther Onkol. 2004;180:695-700.
31. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-22.
32. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-30.
33. Hermanek P, Hutter RV, Sobin LH, et al. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer. 1999;86:2668-73.
34. Tsujinaka T, Fujitani K, Hirao M, et al. Current status of chemoradiotherapy for gastric cancer in Japan. Int J Clin Oncol. 2008;13:117-20.
35. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453-62.
36. Diaz-Gonzalez JA, Rodriguez J, Hernandez-Lizoain JL, et al. Patterns of response after preoperative treatment in gastric cancer. Int J Radiat Oncol Biol Phys. 2011;80:698-704.
37. Kunisaki C, Akiyama H, Nomura M, et al. Comparison of surgical results of D2 versus D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric carcinoma: a multi-institutional study. Ann Surg Oncol. 2006;13:659-67.
38. Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236-42.
39. Marutsuka T, Shimada S, Shiomori K, et al. Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis. Clin Cancer Res. 2003;9:678-85.
40. Kuramoto M, Shimada S, Ikeshima S, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg. 2009;250:242-6.
41. Nagatomo A, Abe N, Takeuchi H, et al. Microscopic cancer cell spread in gastric cancer: whole-section analysis of mesogastrium. Langenbecks Arch Surg. 2009;394:655-60.